Regulatory Affairs
Annual Regulatory GMP/GDP Inspection Survey
Since 2003 EFPIA is being engaged in surveying member companies to map the level of Good Manufacturing Practice (GMP) inspections performed at each of their manufacturing sites. Since the last few years, the survey has included Good Distribution Practice (GDP) inspections and ISO-certifications as well.
Download the Annual Regulatory GMP/GDP Inspection Survey 2022 data
Download the Annual Regulatory GMP/GDP Inspection Survey 2021 data
Download the Annual Regulatory GMP/GDP Inspection Survey 2020 data
Download the Annual Regulatory GMP/GDP Inspection Survey 2019 data
Download the Annual Regulatory GMP/GDP Inspection Survey 2018 data
Download the Annual Regulatory GMP/GDP Inspection Survey 2017 data
Download the Annual Regulatory GMP/GDP Inspection Survey 2016 data
Position papers
Joint EFPIA-IFPMA-Vaccines Europe position on Registration of Multiple Manufacturing Sites in One Product License
Position paper on Expanding Master Files for human medicinal products in the EU/EEA
Position paper on Nitroso-Derivatives of ACE Inhibitors
Position Paper on Nitroso-Derivatives of Dihydropyridine Calcium Channel Blockers (CCBs)
Position Paper on Nitroso-Derivatives of β-blockers and β-agonists
White Paper on Hydrochlorothiazide Investigation into potential N-Nitrosation
Position Paper: Considerations on Good Manufacturing Practice certificates for US manufacturing sites
EFPIA Position Paper on the Use of Multi Attribute Method by mass spectrometry as a QC release and stability tool for biopharmaceuticals - Regulatory Considerations
Reflection paper on EU-US Quality Management System (QMS) Requirements Comparison for Drug-Device Combination Products and Medicinal Products Co-packaged with Medical Devices
Joint Position from EFPIA, IFPMA and Vaccines Europe - Path Forward to Optimise Post-approval Change Management and Facilitate Continuous Supply of Medicines and Vaccines of High Quality Worldwide
EFPIA Reflection Paper on Opportunities and Challenges with Mutual Recognition Agreement (MRA) and Good Manufacturing Practice (GMP)
EFPIA White Paper on Global ICH eCTD Adoption - ES version
Joint Industry Position Paper on Optimising Post-Approval Change Management to Facilitate Continuous Supply of Medicines and Vaccines of High Quality Worldwide (EFPIA, IFPMA and Vaccines Europe)
EFPIA Reflection Paper on the Need for Better Defined Regulatory Pathways in the EU for Digital Health Technologies used concomitantly with Medicinal Products or as drug development tools during Clinical Development
EFPIA Position on Implementation of the ICH E17 Guideline on Planning and Design of Multi-regional Clinical Trials in International Markets & EFPIA ICH E17 Advocacy Toolkit
EFPIA's Position on the Use & Acceptance of Real World Evidence by International Markets
EFPIA Reflection Paper on Autonomous & Portable Manufacturing
EFPIA Reflection Paper on Integral Drug-Device Combination Product Platform Approach
Annex VI to Clinical Trial Regulation 536/2014 – Risk assessment-based concept of an interim solution on expiry date labelling of the immediate packaging of IMPs
AESGP, EFPIA and Medicines for Europe reflections on the EMA-HMA-EC Key principles for electronic Product Information (ePI): IATF reflection paper (press release); IATF ePI report (full paper); IATF ePI report (executive summary); IATF ePI report (annexes); IATF ePI report (no annexes)
EFPIA reflection paper on integrated R&D product support along the product lifecycle
Workflows for quality risk management of nitrosamine risks in medicines
N-nitrosamine Impurities in Biological Medicinal Products
Call for more effective EU regulation of clinical trials with ATMPs consisting of or containing GMOs
Crisis Planning for pharmacovigilance compliance management due to COVID-19 pandemic
Biopharmaceutics Modelling as a fundamental tool to support Accelerated Access
Reflection paper on Regulatory Mitigation Measures for Shortages of medicinal products
Reference Document on Post-Approval Change Management Protocols (PACMPs)
Alternative GMP/GDP Inspection Practices in a Pandemic Situation (COVID‐19) and Beyond
Innovation in Clinical Trial Design: A review of The Clinical Trial Design Landscape
MQEG Discussion Paper: Digitalization in Pharmaceutical Manufacturing
Convergence of Regulatory Requirements benefits Patients and Society
EFPIA's position on expedited regulatory pathways
Optimising regulatory interactions to improve PIPs and PIP procedures
An Industry Perspective About Quality Management System (QMS) for Drug-Device Combination Products
Request for Optimising the GMP paper-based Inspection Process by Regulatory Authorities
Post-approval Changes for Biologics in Latin American Markets
Optimising Post Approval Change Management for Safety Labelling Updates in the Middle East Region
EFPIA position paper on Halal requirements for Pharmaceuticals and Biologicals in ASEAN
EFPIA/EBE/Vaccines Europe Reflection Paper on a Revision of the EU Variations Regulatory Framework
EBE-EFPIA reflection paper - An Industry Perspective on Article 117 of the EU Medical Devices Regulation and the Impact on how Medicines are Assessed
EFPIA Position Paper on the Impact of Non-harmonised Requirements in Local Pharmacopoeias and Opportunities to Promote Alignment of Public Standards
Deletion of test for abnormal toxicity from European pharmacopoeia
Position paper on a Concept for Harmonized Reporting of Inspections
Position paper on Rationale for Removing Abnormal Toxicity Testing
Stability Studies – Proposal for Harmonisation in Latin America
EU Clinical Trial Regulation Annex VI: Labelling of investigational medicinal products and auxiliary medicinal products - Impact on patient safety and validity of study data
EMA / EC CONSULTATIONS
Guideline on clinical investigation of medicinal products in the treatment of depression
EFPIA/VE Final Response to DG Sante Call Comments on Revision of EU Variations Framework & annex to the response
Guide for Assessors of Centralised Applications for the Assessment of SmPC section 5.1
Guideline on Specific Adverse Reaction Follow-up questionnaires (Specific AR FUQ)
Draft revised consolidated 3-year work plan for the Methodology Working Party (MWP)
EFPIA/VE Final Response to DG Sante Call for Evidence on Revision of EU Variations Framework & attachment to response
Reflection paper on criteria to be considered for the evaluation of new active substance (NAS) status of biological substances - EMA/CHMP/CMDh/CAT/BWP/828612/2022
Draft Qualification Opinion for Stride velocity 95th centile as primary endpoint in studies in ambulatory Duchenne Muscular Dystrophy studies - EMA/SA/0000083386
Concept paper on platform trials - EMA/CHMP/840036/2022
Concept Paper on the revision of Annex 11 of the guidelines on Good Manufacturing Practice for medicinal products – Computerised Systems – EMA/INS/GMP/778340/2022
Concept Paper on the Establishment of a Guideline on the Development and Manufacture of Synthetic Peptides - EMA/CHMP/QWP/735422/2022
Concept paper on the revision of the Guideline on the Chemistry of Active Substances - EMA/CHMP/600383/2022
EFPIA response on the EC's proposal (COM(2022) 338 final) on standards of quality and safety for substances of human origin intended for human application and repealing Directives 2002/98/EC and 2004/23/EC
Reflection paper on data required in confirmatory studies of medicinal products for the treatment of Type 2 diabetes - EMA/240473/2022
EMA public consultation concerning The Physical attendance and the Location of Personal residency of the Qualified Person
Guideline on GVP Module XVI Addendum III - Pregnancy prevention programme and other pregnancy-specific risk minimisation measures
Comments on CMDh Multi-Annual Workplan to 2025
EMA Draft guidance document on how to approach the protection of personal data and commercially confidential information in documents uploaded and published in the Clinical Trial Information System (CTIS) - Summary
Draft Qualification Opinion of IMI PREFER
Guideline on core SmPC, Labelling and Package Leaflet for advanced therapy medicinal products (ATMPs) containing genetically modified cells – EMA/CAT/CHMP/158266/2021
ICH guideline S12 on nonclinical biodistribution considerations for gene therapy products - EMA/CHMP/ICH/318372/2021 Step 2b
Targeted Stakeholder consultation on the amendments to the Commission - Implementing Regulation (EU) 520/2012 on pharmacovigilance activities
Draft guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials - EMA/CHMP/BWP/534898/2008 rev. 2 corrigendum
Targeted consultation on the Impact assessment study for the EMA fee system - supplementary comments
Draft guideline on the requirements to the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trails - EMA/CHMP/QWP/31884/2021
Draft EU Common Standard for electronic product information for human medicines (ePI) - EMA/319183/2021 rev. 2
Draft toolbox guidance on scientific elements and regulatory tools to support quality data packages for PRIME marketing authorisation applications - EMA/694114/2019
EFPIA-IFPMA consultation on the PIC/S Strategic Plan 2022-26
Targeted consultation on Blood, Tissue and Cell Regulation & policy options
GVP Module XVI Addendum II - Methods for effectiveness of evaluation - EMA/419982/2019
GVP Module XVI - Risk minimisation measures: selection of tools and effectiveness indicators - EMA/204715/2012 Rev 3
Revision of the EU Legislation on Blood, Tissues and Cells - Targeted and Online public consultations
ICH reflection paper on proposed ICH guideline work to advance patient focused drug development - EMA/CHMP/ICH/415588/2020
Public guidance on Parallel application for EU-M4all (Article 58) opinion and Centralised Marketing Authorisation procedure - EMA/355930/2020
Draft guideline on the evaluation of anticancer medicinal products in man – (EMA/CHMP/205/95 Rev. 6) & Appendix 3 to the guideline
ICH guideline on Q3D (R2) Step 2b on elemental impurities - EMA/CHMP/353369/2013
EFPIA response to public consultation on Inception Impact Assessment
ICH guideline E14/S7B on clinical and nonclinical evaluation of QT/QTc interval prolongation and proarrhythmic potential - Q&As
ICH guideline M7 on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk - questions & answers, Step 2b
Revision of Annex 1 of EU GMP Guide
Response to EDQM proposed text published in Pharmeuropa 32.2 for N-Nitrosamines in Active Substances
Responses to EDQM proposed texts published in Pharmeuropa 32.2 for Plastics
Questionnaire on new genomic techniques to contribute to the study requested by the Council
Points to Consider on implications of Coronavirus disease (COVID-19) on methodological aspects of ongoing clinical trials - EMA/158330/2020
Reflection paper on Good Manufacturing Practice and Marketing Authorisation Holders - EMA/457570/2019
GVP Product- or Population-Specific Considerations III: Pregnant and breastfeeding women - EMA/653036/2019
Preparedness of medicines' clinical trials in paediatrics - Recommendations by the Enpr-EMA working group on trial preparedness - EMA/56009/2019 Corr. 1
EU Commission's Inception Impact Assessment for Revision of the EMA fee system - Annex
Draft qualification opinion of clinically interpretable treatment effect measures based on recurrent event endpoints that allow for efficient statistical analyses - EMA/CHMP/SAWP/291384/2019
ICH guideline E19 on optimisation of safety data collection (Step 2) - EMA/CHMP/ICH/173706/2019
ICH guideline E8(R1) on general considerations for clinical studies - Step 2b - EMA/CHMP/ICH/544570/1998
Draft qualification opinion of Multiple Sclerosis clinical outcome assessment (MSCOA) - EMA/CHMP/SAWP/336445/2019
Reflection paper on the qualification of non-genotoxic impurities - EMA/CHMP/SWP/545588/2017
ICH guideline M10 on bioanalytical method validation - EMA/CHMP/ICH/172948/2019
Electronic Product Information for Human Medicines in the EU - Draft Key Principles
Draft questions and answers on Data Monitoring Committees issues - EMA/492010/2018
Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections, Rev. 3 - EMA/844951/2018
Discussion paper: Use of patient disease registries for regulatory purposes – methodological and operational considerations - EMA/763513/2018
Guideline on the environmental risk assessment of medicinal products for human use - EMEA/CHMP/SWP/4447/00 Rev. 1
Guideline on quality and equivalence of topical products - CHMP/QWP/708282/2018
Guideline on the quality of water for pharmaceutical use - EMA/CHMP/CVMP/496873/2018
Targeted consultation on the guideline on the format and content of applications for designation as orphan medicinal products and on the transfer of designations from one sponsor to another - ENTR/6283/00 Rev 5
Concept paper on the revision of the guideline on the evaluation of anticancer medicinal products in man - EMA/CHMP/755489/2018
Good practice guidance for communication on medicines' availability issues - EMA/632473/2018
ICH guideline S11 on nonclinical safety testing in support of development of paediatric medicines - Step 2b - EMA/CHMP/ICH/616110/2019
eSource Direct Capture (DDC) qualification opinion - EMA/282576/2018
Draft guideline on clinical investigation of medicinal products in the treatment of epileptic disorders - Revision 3 - CHMP/EWP/566/98
Response to EU Ombudsman - Strategic inquiry into pre-submission activities organised by the European Medicines Agency - OI/7/2017/KR
ICH guideline M9 on biopharmaceutics classification system based biowaivers - EMA/CHMP/ICH/493213/2018
ICH Guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management Step 2b - EMA/CHMP/ICH/804273/2017
Concept paper on the need for revision of the guideline on the investigation of medicinal products in the term and preterm neonate - EMA/PDCO/362462/2016
Guideline on the Use of Minimal Residual Disease as a Clinical Endpoint in Multiple Myeloma Studies - EMA/CHMP/459559/2018
Draft addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections to address paediatric-specific clinical data requirements - First version - EMA/CHMP/187859/2017
Concept paper on preparation of a revised guideline on the evaluation of medicinal products indicated for treatment of bacterial infections - EMA/CHMP/75653/2018
Guideline on the responsibilities of the sponsor with regard to handling and shipping of investigational medicinal products for human use in accordance with Good Clinical Practice and Good Manufacturing Practice - EMA/202679/2018
Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus - CPMP/EWP/1080/00 Rev. 2
Reflection paper on investigation of pharmacokinetics and pharmacodynamics in the obese population - EMA/CHMP/535116/2016
Public consultation concerning the European Union template for good manufacturing practice (GMP) non-compliance statement - EMA/189939/2018
Draft guideline on the clinical evaluation of medicinal products indicated for the prophylaxis or treatment of respiratory syncytial virus (RSV) disease - EMA/CHMP/257022/2017
Reflection paper on statistical methodology for the comparative assessment of quality attributes in drug development - EMA/CHMP/138502/2017
Annex 1 on manufacturing of sterile medicinal products - Revision
EFPIA, AESGP and MfE response to EMA consultation on Initiatives for electronic EU product information - (Annex 1); (Annex 2)
ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials - EMA/CHMP/ICH/436221/2017
Reflection paper on the pharmaceutical development of medicines for use in the older population (First version) - EMA/CHMP/QWP/292439/2017
Reflection paper on the use of extrapolation in the development of medicines for paediatrics - EMA/199678/2016
CMDh Guidance on the Informal Work-Sharing procedure for follow-up for PSUSA for NPAs - CMDh/367/2017
Roadmap on the Evaluation of the legislation on medicines for children and rare diseases (medicines for special populations)
Concept paper on predictive biomarker-based assay development in the context of drug development and lifecycle - EMA/CHMP/800914/2016
GVP Product- or Population-Specific Considerations IV: Paediatric population (EMA/572054/2016)
Guideline on equivalence studies for the demonstration of therapeutic equivalence for products that are locally applied, locally acting in the gastrointestinal tract as addendum to the guideline on the clinical requirements for locally applied, locally acting products containing known constituents - CPMP/EWP/239/95 Rev. 1
Draft guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol – EMA/430909/2016
Concept paper on the revision of the guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population – EMA/CHMP/448599/2016
Draft guideline on good-clinical-practice compliance in relation to trials master file (paper and/or electronic) for content, management, archiving, audit and inspection of clinical trials – EMA/15975/2016
Concept paper on a guideline on the evaluation of medicinal products indicated for treatment of influenza (EMA/CHMP/EWP/808940/2016)
Draft guideline on multiplicity issues in clinical trials - EMA/CHMP/44762/2017
Concept paper on the need to revise Condition – Specific guidance, Appendix 4 to the guideline on the evaluation of anticancer medicinal products in man – EMA/CHMP/102314/2017
Concept paper on a revision of the guideline on the investigation of drug interactions – EMEA/CHMP/694687/2016
Concept paper on revision of the guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for the treatment of asthma in children and adolescents – EMA/CHMP/267194/2016
Target stakeholder consultation on the revised guidelines on excipients in the labelling and package leaflet of medicinal products for human use
EMA policy on access to documents - EMA/729522/2016
Questions and answers on implementation of risk based prevention of cross contamination in production and ‘Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities’ (EMA/CHMP/CVMP/SWP/169430/2012)
ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological / biological entities) – questions and answers – EMA/CHMP/ICH/809509/2016
ICH E11 (R1) guideline on clinical investigation of medicinal products in the pediatric population - EMA/CPMP/ICH/2711/1999
Concept paper on the need for revision of the guideline on clinical investigation of medicinal products in the treatment of depression– EMA/CHMP/183826/2016
Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products (EMA/CHMP/SWP/28367/07 Rev. 1)
Draft Regulation on GMP for IMPs
Implementing Directive on Principles and guideline on good manufacturing practices for medicinal products for human use
Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation - EMA/CHMP/458101/2016
Concept paper on reparation of a guideline on the evaluation of medicinal products indicated for the treatment and prophylaxis of respiratory syncytial virus (RSV) infection - EMA/CHMP/360458/2016
Concept paper on the need for revision of the guideline on clinical investigation of medicinal product for the treatment of migraine - EMA/CHMP/179671/2016
Guideline on the development of new medicinal products for the treatment of ulcerative colitis - EMA/EWP/18463/2006 Rev. 1
Guideline on the development of new medicinal products for the treatment of Crohn's
Addendum to the 'guideline on the evaluation of medicinal products indicated for treatment of bacterial infections' to address the clinical development of new agents to treat disease due to Mycobacterium tuberculosis - EMA/CHMP/EWP/14377/2008 Rev. 1
Concept paper on Good Manufacturing Practice and Marketing Authorisation Holders - EMA/582064/2016
Draft guideline on good pharmacovigilance practices (GVP) - Module IX and Addendum I
Draft guideline on evaluation of anticancer medicinal products in man - EMA/CHMP/205/95 Rev. 5
EFPIA-EBE comments on good pharmacogenomics practice - EMA/CHMP/268544/2016
Draft implementation strategy of ICH Q3D guideline EMA/404489/2016
Summary of Clinical Trial Results for Laypersons
Risk proportionate approaches in clinical trials
Ethical Considerations for Clinical Trials on Medicinal products conducted with Minors
Guideline on good pharmacovigilance practices (GVP) - Module XV (Rev 1) - EMA/118465/2012
AESGP EFPIA and EGA Response to NIVEL Study Reports PIL-S and PIL-BOX - January 2016
Draft guideline on manufacture of the finished dosage form - EMA/CHMP/QWP/245074/2015
Annex 17 on Real Time Release Testing
Draft guideline on the chemistry of active substances - EMA/CHMP/QWP/96664/2015
Draft guideline on the processing of renewals in the centralised procedure - EMA/CHMP/2990/00 Rev. 5
Concept paper on new guidance for importers of medicinal products - EMA/2382299/2015
EU Telematics Strategy and Implementation Roadmap 2015-2017 - EMA/201512/2015
Good practice guide on risk minimisation and prevention of medication errors - EMA/606103/2014
Concept paper on good genomics biomarker practices- EMA/CHMP/PGWP/415990/2014
Draft revision of EudraVigilance access policy for medicines for human use – EMA/759287/2009 Rev. 1
Draft European Union individual case safety report (ICSR) implementation guide – EMA/51938/2013